Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 17234747.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Oncolytic viruses that can destroy cancer cells have been engineered in a variety of ways with the aim of improving their selectivity and efficacy. Here, we review data from clinical investigations of these virotherapeutic agents, specifically those that have shown systemic efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus. Further directions for optimizing i.v. delivery and efficacy are discussed.
Medical subject headings
- Neoplasms
- Oncolytic Virotherapy